Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy

Federico Pirro, Ketty Peris, Giacomo Caldarola, Giuseppe Annibale Micheli, Arianna Zangrilli, Nicoletta Bernardini, Mauro Bavetta, Dario Graceffa, Claudio Bonifati, Franca Cantoresi, Sara Faleri, Domenico Giordano, Adriana Micheli, Gaia Moretta, Gianluca Pagnanelli, Vincenzo Panasiti, Alessia Provini, Antonio Richetta, Lidia Sacchelli, Luca Bianchi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Introduction: Efficacy of anti-TNF-a agents seems inferior to IL-17 and IL-23 inhibitors. Nevertheless, after biosimilars approval, anti TNF-a agents are recommended as first-line for psoriatic patients, for economic reasons. Methods: Predictive factors of response or non-response to adalimumab in bionaive patients who started adalimumab (originator or biosimilar) over 12 years in 9 dermatologic centers in Italy. Effectiveness was assessed with Psoriasis Area and Severity Index (PASI75 and PASI90) at weeks 12, 24 and 48. Multiple logistic regressions were used for variables predicting clinical response; Kaplan–Meier survival curves and Cox regression for drug survival. Results: The drug survival analysis showed reduced hazard ratio of overall discontinuation with male gender and scalp localization. In contrast, baseline PASI and genital psoriasis were significantly associated with increased risk of overall discontinuation. Predictive factors of non-response seemed elevated in patients with baseline PASI, older age groups, previously treated patients with phototherapy, females or patients with palmo-plantar while scalp psoriasis, previous cyclosporine and acitretin appeared as a positive predictive factor. Conclusions: This real-life analysis might be useful for clinicians in case of bio-naive patients with moderate-to-severe psoriasis and various comorbidities.
Lingua originaleEnglish
pagine (da-a)1291-1298
Numero di pagine8
RivistaExpert Opinion on Biological Therapy
Volume21
DOI
Stato di pubblicazionePubblicato - 2021

Keywords

  • anti TNF a
  • biotechnological therapies
  • predictive factors
  • Moderate-to-severe psoriasis
  • high need patients

Fingerprint

Entra nei temi di ricerca di 'Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy'. Insieme formano una fingerprint unica.

Cita questo